Monitoring pediatric antidepressant use.
The PhaST system was developed to improve monitoring efforts of pediatric antidepressant use and is currently being tested in a clinical trial. The design of PhaST reflects both the FDA recommendations and consideration of system and family resources. Pilot and preliminary results of the current study data have shown that participants can be reached by telephone and necessary monitoring calls can be completed over a period of time. PTS clinicians were also able to respond to "positive calls" and determine level of concern as well as action steps needed. Physicians and other ongoing providers received monitoring call reports and PTS clinician follow-up as indicated. Given the promising findings of the pilot study and preliminary trial data, PhaST appears to be a sensitive method for monitoring outpatients for adverse effects of antidepressants. Because it uses inexpensive IVR technology and physician extenders, it may prove to increase communication between health providers and patients and shows promise for improving patient safety and quality of care. Beyond medication safety, it could also be utilized to enhance medication and/or treatment adherence, as well as assist clinicians in helping patients implement behavior management plans.